Pacific Biosciences of California Inc.
PACB | NASDAQ
$1.36
-$0.01 (-0.73%)
At close: Sep 21, 2026, 4:00 PM ET
$1.38
+$0.02 (+1.24%)
Pre-market:
Sep 22, 2026, 4:21 AM ET
Company Profile
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Key Executives
| Name | Position |
|---|---|
| Mark Van Oene | President, Chief Executive Officer & Director |
| Natalie Welch | Chief People Officer |
| Brett Atkins | General Counsel & Corporate Secretary |
| Christian O. Henry | Senior Business Advisor & Director |
| James R. Gibson | CFO & Principal Accounting Officer |
| Stephen Turner | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 4 | Filing |
| Aug 07, 2026 | S-8 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 09, 2026 | 8-K | Current Report |
| Jun 04, 2026 | 4 | Filing |
| Jun 04, 2026 | 4 | Filing |
| Jun 04, 2026 | 4 | Filing |
Pacific Biosciences of California Inc.
| Country | United States |
| IPO Date | Oct 26, 2010 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 485 |
| CEO | Mark Van Oene |
Contact Details
1305 O’Brien Drive Menlo Park,
California 94025 United States
Stock Details
| Ticker Symbol | PACB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001299130 |
| CUSIP Number | 69404D108 |
| ISIN Number | US69404D1081 |
| SIC Code | 3826 |
Add to Watchlist
Select watchlists to add or remove PACB